Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression. by Chemaitelly, Hiam et al.
157Chemaitelly H, et al. Sex Transm Infect 2021;97:157–169. doi:10.1136/sextrans-2020-054515
Epidemiology
Original research
Global epidemiology of Neisseria gonorrhoeae in 
infertile populations: systematic review, meta- 
analysis and metaregression
Hiam Chemaitelly,1 Alzahraa Majed,1 Farah Abu- Hijleh,2 Karel Blondeel,3,4 
Thabo Christopher Matsaseng,3,5 James Kiarie,3 Igor Toskin,3 Laith J Abu- Raddad   1,6
To cite: Chemaitelly H, 
Majed A, Abu- Hijleh F, 
et al. Sex Transm Infect 
2021;97:157–169.
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
sextrans- 2020- 054515).
For numbered affiliations see 
end of article.
Correspondence to
Mrs Hiam Chemaitelly and Dr 
Laith J Abu- Raddad, Infectious 
Disease Epidemiology Group, 
Weill Cornell Medicine- 
Qatar, Cornell University, 
Qatar- Foundation, Education 
City, Doha 24144, Qatar;  
hsc2001@ qatar- med. cornell. 
edu,  lja2002@ qatar- med. 
cornell. edu and Dr Igor Toskin, 
Department of Reproductive 
Health and Research, World 
Health Organization, Geneva, 
Switzerland;  toskini@ who. int
Received 5 April 2020
Accepted 14 April 2020
Published Online First 
18 May 2020
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
AbsTrACT
Objective To provide an in- depth systematic 
assessment of the global epidemiology of gonorrhoea 
infection in infertile populations.
Methods A systematic literature review was 
conducted up to 29 April 2019 on international 
databases and WHO regional databases, and 
reported following Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses guidelines. 
All prevalence measures of gonorrhoea infection 
among infertile populations, based on primary 
data, qualified for inclusion. Infertile populations 
were broadly defined to encompass women/men 
undergoing infertility evaluation or treatment 
(infertility clinic attendees and partners). Pooled 
mean prevalence by relevant strata was estimated 
using random- effects meta- analysis. Associations 
with prevalence and sources of heterogeneity were 
explored using metaregression. Risk of bias was 
assessed using four quality domains.
Findings A total of 147 gonorrhoea prevalence 
studies were identified from 56 countries. The pooled 
mean prevalence of current gonorrhoea infection was 
estimated globally at 2.2% (95% CI 1.3% to 3.2%), 
with the highest prevalence in Africa at 5.0% (95% CI 
1.9% to 9.3%). The mean prevalence was higher for 
populations with tubal factor infertility (3.6%, 95% 
CI 0.9%–7.7%) and mixed cause and unexplained 
infertility (3.6%, 95% CI 0.0% to 11.6%) compared 
with other diagnoses, such as ovarian and non- tubal 
infertility (0.1%, 95% CI 0.0% to 0.8%), and for 
secondary (2.5%, 95% CI 0.2% to 6.5%) compared 
with primary (0.5%, 95% CI 0.0% to 1.7%) infertility. 
Metaregression identified evidence of variations in 
prevalence by region and by infertility diagnosis, 
higher prevalence in women than men and a small- 
study effect. There was a trend of declining prevalence 
by about 3% per year over the last four decades 
(OR=0.97, 95% CI 0.95 to 0.99).
Conclusions Gonorrhoea prevalence in infertile 
populations is several folds higher than that in the 
general population, with even higher prevalence in 
women with tubal factor infertility and in individuals 
with secondary infertility. These findings support the 
potential role of gonorrhoea in infertility and suggest 
that some infertility is possibly preventable by controlling 
gonorrhoea transmission.
PrOsPErO registration number CRD42018102934.
InTrOduCTIOn
Infertility, ‘a disease characterised by failure to 
establish clinical pregnancy after 12 months of 
regular, unprotected sexual intercourse’,1 2 affects 
~2% of reproductive- age women with no prior live 
birth and >10% of those with an earlier successful 
delivery.3 While infertility in men remains poorly 
quantified,4 available estimates by world region 
suggest a range of 2.5%–12.0%.5
A potential contributor to infertility, for both 
women and men, is a common STI caused by the 
bacterium Neisseria gonorrhoeae,6 in addition to 
Chlamydia trachomatis (CT).7–10 In 2016, the 
WHO estimated that nearly 87 million individuals 
acquired this infection globally, with incidence rates 
estimated at 20 per 1000 women and 26 per 1000 
men.11 In women, gonorrhoea is often asympto-
matic, complicating early detection and treatment 
and increasing their risk of cervicitis and pelvic 
inflammatory disease,12 13 while in men, it has been 
associated with epididymitis, epididymo- orchitis 
and chronic prostatitis.14–17 Untreated, these condi-
tions may lead to subfertility/infertility.12 14 15 18
Despite their health, social and economic impli-
cations,19 20 STIs and infertility have long been a 
low priority on national policy agendas. Recently, 
the WHO formulated the ‘Global Health Sector 
Strategy on STIs, 2016–2021’, with the goal of 
ending STI epidemics as a public health concern 
by 2030.21 A key target is achieving by 2030 a 
90% reduction in N. gonorrhoeae incidence.21 The 
urgency in addressing gonorrhoea is compounded 
by its recent classification as a ‘superbug’,22 given 
the widespread antimicrobial resistance, even to 
infection’s last- line treatment.23–26 Consequently, 
the WHO launched a global action plan to 
control gonorrhoea transmission and sequelae,27 28 
including building a business case for the global 
public health value of gonococcal vaccines.29 30 
Achieving WHO set targets entails fulfilment of five 
strategic directions/actions; the first is to understand 
the STI epidemic and burden, including subfertility/
infertility, as a basis for advocacy, political commit-
ment, national planning, resource mobilisation 
and allocation, implementation and programme 
improvement.21
This study was motivated by our recent work 
assessing CT prevalence levels in different at- risk 
populations in the Middle East and North Africa, 
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where we identified an association between CT prevalence and 
infertility, with prevalence among infertile populations being 
three- fold higher than that among the general population.10 The 
present study aimed to characterise the global epidemiology of 
gonorrhoea infection in infertile populations by (1) systemati-
cally reviewing and synthesising evidence of infection prevalence, 
(2) estimating the pooled mean prevalence, stratified by WHO 
region among other key factors, and (3) exploring population- 
level associations with prevalence and sources of between- study 
heterogeneity.
Longitudinal studies examining gonorrhoea’s adverse health 
outcomes (a curable infection) are difficult/unethical to conduct. 
A recent study attempted to overcome this challenge through 
linking national testing databases to hospital records, but iden-
tified too few cases to reach conclusive evidence about gonor-
rhoea’s role in infertility.31 In the absence of direct evidence, 
our study aimed to provide indirect evidence for a link between 
gonorrhoea and infertility but strictly did not aim to nor can 
it establish causality. The underlying hypothesis is that current 
infection is of unknown duration and persistence to establish a 
causal link with infertility, but is often predictive of past expo-
sure.32–34 This assertion is supported by several lines of evidence. 
It is established through tens of studies of different designs that 
gonorrhoea as well as chlamydia, being curable infections, carry 
a high risk of reinfection because of re- exposure to the same 
sexual partner or to other high- risk partners.33 35–37 As such, it can 
be assumed that a current gonorrhoea infection is strongly indic-
ative of a previous gonorrhoea infection33 38 39; indeed studies 
have shown that the strongest predictor of current gonorrhoea 
infection is a history of gonorrhoea infection.32 40 For example, 
in the UK, a history of gonorrhoea infection was found to be 
the strongest predictor of current gonorrhoea infection even 
after controlling for other demographic and behavioural factors 
(adjusted OR 4.36, 95% CI 1.78 to 10.71).32
It is also established that there are strong correlations between 
exposure and the prevalence of different STIs, such as gonor-
rhoea and chlamydia,41 42 herpes simplex virus type 2 (HSV-2) 
and HIV43–45 (beyond the debated biological synergy46), even 
though these STIs could be acquired at different time frames. As 
such, exposure to an STI is a predictor of exposure to another 
STI. For instance, HSV-2 is often used as a proxy biomarker for 
HIV exposure and epidemic potential.43–45 Just as STI exposures 
acquired at different time points are correlated with each other, 
it is reasonable to expect that measures of gonorrhoea preva-
lence assessed at different times in the same population are also 
correlated.32 40 This is because, fundamentally, the driving factor 
of STI exposure is sexual risk behaviour47; current gonorrhoea 
infection in a population/person can be seen as a proxy of the 
past and present sexual risk behaviour of that population/person 
or person’s sexual partners.48 49 Studies also show that people 
tend to be consistent in their sexual risk behaviour over at least 
a few years’ duration.50–52
METhOds
Detailed methodology has been previously published as a study 
protocol.53 A brief description is provided as follows.
search strategy and selection criteria
A systematic review of gonorrhoea prevalence in infertile popu-
lations was conducted following Cochrane Collaboration guide-
lines,54 and reported following the Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses guidelines55 (checklist in 
online supplementary table 1).
Literature was searched, up to 29 April 2019 on PubMed and 
Embase, and up to 5 February 2019 on the WHO Index Medicus 
regional databases, using broad terms with no language or year 
restrictions (online supplementary box 1). Duplicate citations 
were excluded using a reference manager, EndNote (Thomson 
Reuters, USA). Title and abstract screening and full- text screening 
of relevant/potentially relevant citations were performed by HC 
and AM. Reference lists of reviews and relevant articles were 
further hand- searched.
Any article reporting prevalence of current urogenital infection 
or serological markers of gonorrhoea in infertile populations, 
based on primary data, qualified for inclusion. Infertile popula-
tions were broadly defined to include women/men undergoing 
infertility evaluation or treatment (infertility clinic attendees and 
partners). Studies in voluntarily sterile populations, based on the 
infection’s self- report, including <10 participants, or assessing 
gonorrhoea in tissue samples from the upper genital tract, were 
excluded.
data extraction and synthesis
Data were extracted by HC and AM and double extracted by 
FA (extraction list in online supplementary box 2). In addition 
to the overall gonorrhoea measure, stratified measures were 
extracted whenever a stratum included ≥10 participants.
Studies assessing gonorrhoea using different assay types 
(nucleic acid amplification test (NAAT), culture, Gram stain and 
Ig among others) were extracted separately for different analyses. 
Studies applying the same assay to different biological specimens 
were included once based on a predefined order prioritising, for 
women, gonorrhoea detection in endocervical swabs, followed 
by vaginal and urine samples; and for men, detection in urethral 
swabs, followed by urine and semen samples.
risk of bias and precision assessments
Informed by the Cochrane approach54 and existing litera-
ture,56–59 each study was rated as having ‘low’ versus ‘high’ risk 
of bias on four quality domains: (1) validity of infertility defini-
tion (follows WHO definition vs otherwise), (2) lack of exposure 
to antimicrobials for ≥1 week prior to collection of biological 
samples (ascertained vs otherwise), (3) consistency in assay used 
for infection ascertainment (same assay used to test all partici-
pants vs otherwise) and (4) response rate (≥80% vs <80%). A 
study with missing information for a specific domain was consid-
ered as having ‘unclear’ risk of bias for that domain. A study was 
deemed of ‘higher’ precision if its original sample tested ≥100 
participants.
Meta-analysis
Pooled mean gonorrhoea prevalence and 95% CIs were esti-
mated using random- effects meta- analysis. Here, overall prev-
alence was replaced by strata, whenever possible. For each 
study, only one final stratification was considered, based on a 
predefined priority order: country, sex, infertility diagnosis, 
infertility type, age and year of data collection. Stratified meta- 
analyses by relevant factors were further performed, and hetero-
geneity assessment was conducted.60 61
Metaregression
Metaregression analyses were conducted to explore sources of 
between- study heterogeneity and to examine associations with 
prevalence for the following predefined factors: WHO region 
(African region (AFRO), Americas (AMRO), Eastern Mediter-
ranean (EMRO), European (EURO), Southeast Asia (SEARO), 
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Figure 1 Flowchart of the study selection process for the global systematic review of Neisseria gonorrhoeae infection prevalence in infertile 
populations, following the Preferred Reporting Items for Systematic Reviews and Meta- Analyses guidelines.55
Western Pacific (WPRO)), sex, infertility type, infertility diag-
nosis, presence of urogenital signs and symptoms, assay type, 
median year of data collection, sample size/precision (to assess 
small- study effect) and risk of bias domains. Variables’ details/
subgroupings are in online supplementary box 2 and online 
supplementary table 2.
Strength of evidence for an association with prevalence 
was deemed ‘good’ at 0.05<p value≤0.10 and ‘strong’ at p 
value≤0.05. Sensitivity analysis focusing on studies assessing 
current infection was performed.
rEsulTs
search results and scope of evidence
Figure 1 shows the study selection process. Search identified 
9937 citations: 3603 through PubMed, 5141 through Embase 
and 1193 through the WHO Index Medicus databases. After 
excluding duplicates and screening titles and abstracts, 1410 
unique reports underwent full- text screening. Of these, 89 were 
eligible for inclusion. The rest were excluded for reasons outlined 
in figure 1. Twenty- six additional reports were identified through 
reference list hand- searching. In sum, 115 reports contributing 
147 gonorrhoea prevalence studies were included in the review. 
These yielded 184 stratified measures for meta- analyses.
There were 27 264 gonorrhoea test results from 56 countries. 
EURO contributed 44.2% of studies (n=65), AMRO 16.3% 
(n=24), AFRO 13.6% (n=20), SEARO 8.2% (n=12), WPRO 
and EMRO 7.5% (n=11) each, and multicentre/multiregional 
studies 2.7% (n=4). Most studies (n=107, 72.8%) assessed 
current infection, of which 26.2% were NAAT- based; 67.3% 
were culture- based; and 6.5% were Gram stain/gonozyme/
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fluorescent antibody- based. The rest either reported ever infec-
tion using IgG (n=20, 13.6%) or IgA (n=3, 2.0%), or were 
based on unclear assays (n=17, 11.6%). Studies are detailed in 
online supplementary tables 3-8.
Prevalence overview
Reported current infection prevalence across regions ranged from 
0% to 53.0% (online supplementary tables 3-8). The median 
was 0%, as 57 out of 107 studies reported zero prevalence; it is 
difficult to identify a positive case for a low- prevalence infection 
in a study of a small sample size. The highest median current 
infection prevalence was for AFRO at 3.3%. Ever infection 
prevalence (IgG) ranged from 1.3% to 65.0%, with a median of 
25.0%; the median per region ranged from 2.5% in EMRO to 
39.1% in AFRO (online supplementary tables 3-8).
risk of bias and precision assessments
Online supplementary tables 9 and 10 show the summarised 
and study- specific precision and risk of bias assessments. Briefly, 
50.3% of studies were of higher precision (≥100 participants). 
Over a third (34.7%) followed WHO infertility definition; 1.3% 
included infertile participants for <12 months, while the rest 
(64.0%) did not report an infertility definition. Only 14.3% of 
studies excluded infertile participants exposed to antimicrobials 
in the week prior to sample collection; 6.1% may have included 
such participants; and information was missing for the rest 
of studies (79.6%). Almost all studies (96.6%) demonstrated 
consistency in gonorrhoea testing across infertile participants. 
Response rate was mostly unavailable (97.3%); studies were 
almost entirely facility/clinic- based or retrospective charts were 
review- based.
Studies were overall of reasonable quality (online supplemen-
tary table 9). Nearly all (98.6%) had low risk of bias in ≥1 quality 
domain and 41.5% had low risk of bias in ≥2 domains. Mean-
while, only 8.8% had high risk of bias in ≥1 quality domain and 
<1% had high risk of bias in ≥2 domains. Over 90% of studies 
had unclear risk of bias in ≥2 domains.
summary estimates of pooled mean gonorrhea prevalence
Forest plots showing meta- analysis results for studies reporting 
current infection prevalence, by relevant strata, are in figure 2 
and online supplementary figures 1-14.
Pooled mean prevalence of current gonorrhoea infection was 
globally at 2.2% (95% CI 1.3% to 3.2%), and regionally at 5.0% 
(95% CI 1.9% to 9.3%) in AFRO, 2.7% (95% CI 0.6% to 5.8%) 
in EMRO, 2.5% (95% CI 0.4% to 5.7%) in WPRO, 2.4% (95% 
CI 0.8% to 4.5%) in EURO, 1.0% (95% CI 0.0% to 3.4%) in 
AMRO and 0.0% (95% CI 0.0% to 0.06%) in SEARO (table 1). 
Meanwhile, mean ever infection prevalence was globally at 
21.0% (95% CI 13.2% to 30.0%) and varied regionally from 
5.4% (95% CI 1.2% to 12.0%) in AMRO to 46.6% (95% CI 
28.4% to 65.3%) in AFRO (table 1).
Estimates varied by infertility diagnosis (table 1). Mean current 
infection prevalence was 3.6% (95% CI 0.9% to 7.7%) for 
tubal factor infertility (TFI), 3.6% (95% CI 0.0% to 11.6%) for 
mixed (samples combining different diagnoses) and unexplained 
infertility, 2.6% (95% CI 1.1% to 4.5%) for general/unspeci-
fied infertility, 1.4% (95% CI 0.2% to 3.3%) for male factor 
infertility and 0.06% (95% CI 0.0% to 0.8%) for ovarian and 
non- TFI infertility. This measure was also 2.5% for secondary 
infertility (95% CI 0.2% to 6.5%) and 0.5% for primary infer-
tility (95% CI 0.0% to 1.7%).
Mean current infection prevalence varied by assay type: 0.7% 
(95% CI 0.08% to 1.6%) using NAAT, 2.7% (95% CI 1.4% to 
4.3%) using culture, 3.8% (95% CI 0.0% to 24.4%) using other 
assays assessing current infection and 8.7% (95% CI 0.0% to 
31.3%) using Gram stain (table 1).
Mean current infection prevalence was 2.5% in women (95% 
CI 1.2% to 4.1%) vs 1.5% in men (95% CI 0.5% to 3.0%), 3.0% 
in studies before 2005 (95% CI 1.5% to 4.8%) vs 1.1% in those 
after 2005 (95% CI 0.4% to 2.0%), 4.1% in samples including 
<100 participants (95% CI 1.8% to 6.9%) vs 1.0% in those 
including ≥100 participants (95% CI 0.3% to 1.9%) and 16.2% 
in symptomatic individuals (95% CI 7.1% to 27.7%) vs 1.0% in 
asymptomatic ones (95% CI 0.3% to 2.0%) (table 1).
Mean ever infection prevalence showed similar results, 
although at much higher prevalence levels (table 1).
There was evidence for heterogeneity in prevalence across 
studies. Most meta- analyses showed a p value of <0.001 for 
Cochran’s Q statistic, wide prediction intervals indicating high 
heterogeneity and I2≥70%, affirming most variability as due to 
true differences in prevalence across studies rather than chance 
(table 1).
Associations with prevalence and sources of between-study 
heterogeneity
Univariable metaregression results are in table 2. There was 
‘strong’ evidence for an association with prevalence (p value 
of ≤0.05) for WHO region, sex, infertility diagnosis, pres-
ence of urogenital signs and symptoms, assay type, year of data 
collection, sample size and exposure to antimicrobials prior to 
sample collection; ‘good’ evidence for infertility type (0.05<p 
value≤0.10), but no evidence for validity of infertility defini-
tion, consistency in assay used for infection ascertainment and 
response rate.
Compared with AMRO, AFRO showed four- fold higher odds 
of gonorrhoea infection (OR=4.0, 95% CI 1.5 to 10.1), while 
no significant differences were found for the other regions. 
Women had twice higher odds of infection than men (OR=2.0, 
95% CI 1.1 to 3.7). Individuals with secondary infertility also 
had twice higher odds of infection (OR=2.1, 95% CI 0.9 to 
5.2) than those with primary infertility. Odds were 2.4- fold 
(95% CI 1.2 to 4.6) and 2.0- fold (95% CI 0.8 to 5.0) higher 
for women with TFI and for individuals with mixed cause and 
unexplained infertility, respectively, compared with those with 
general/unspecified infertility. Symptomatic individuals had six- 
fold higher odds of infection compared with asymptomatic ones 
(OR=5.9, 95% CI 2.6 to 13.5).
Culture and other assays detecting current infection showed 
2.5- fold (95% CI 1.3 to 4.8) and 4.1- fold (95% CI 1.1 to 15.3) 
higher odds, respectively, compared with NAAT, while assays 
detecting IgG showed 22.1- fold higher odds (95% CI 9.5 to 
51.2). There was evidence for declining prevalence at ~3% per 
year over the last four decades (OR=0.97, 95% CI 0.95 to 0.99) 
and for small- study effect, with studies including ≥100 partici-
pants showing lower prevalence (OR=0.5, 95% CI 0.3 to 0.9).
Sensitivity analysis using only studies assessing current gonor-
rhoea infection affirmed the aforementioned results, although 
some associations failed to reach statistical significance because 
of the smaller number of studies (online supplementary table 
11).
Full multivariable metaregression analysis could not be 
performed due to lack of statistical power.62 However, backward 
variable selection yielded a final multivariable model including 
four predictors: region, presence of urogenital signs and 
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Figure 2 Forest plots showing key results of the meta- analysis on studies reporting the prevalence of current NG infection in infertile populations 
for (A) the WHO -African Region, (B) tubal factor infertility and (C) secondary infertility. NG, Neisseria gonorrhoeae.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































symptoms, sample size and assay type (p value of ≤0.1, online 
supplementary table 12). The analysis confirmed the univariable 
metaregression results.
dIsCussIOn
We provided, to our knowledge, the first systematic review of 
gonorrhoea infection in infertile populations. Current infection 
prevalence was several folds higher than that in the general popu-
lation; the global estimate in infertile populations was 2.2%, 
compared with only 0.8% in the general population (per WHO 
2016 estimates).11 Regional estimates followed a similar pattern. 
Current infection prevalence rates in infertile versus the general 
population were 5.0% vs 1.8%11 in AFRO, 2.7% vs 0.7%11 
in EMRO, 2.5% vs 0.8%11 in WPRO, and 2.4% vs 0.3%11 in 
EURO, respectively. These findings should be seen against the 
expectation that infertile populations should be prone to a lower 
prevalence than the general population; there is higher frequency 
of STI testing among them, and therefore earlier detection and 
higher treatment coverage relative to the general population. 
Infertile populations may also undergo prophylactic antibiotic 
administration, not necessarily with testing, prior to procedures 
such as in vitro fertilisation/embryo transfer.63 64
Higher prevalence was also associated with conditions conven-
tionally considered as sequelae of gonorrhoea infection,12 such 
as TFI and secondary infertility. TFI was associated with two- 
fold higher odds of gonorrhoea infection. The biological plausi-
bility behind this association has been repeatedly described, with 
evidence showing that untreated gonococcal infection can lead 
to pathogen ascension to the upper genital tract, causing pelvic 
inflammatory disease, tubal scarring, oviduct occlusion and 
internal tissue adhesion.12 18 65 Higher prevalence was also found 
in individuals with mixed and unexplained infertility diagnoses. 
However, samples comprising mixed infertility diagnoses often 
included individuals with TFI, while more studies are needed 
to elucidate the association with unexplained infertility. Preva-
lence was further higher in individuals with secondary infertility, 
possibly because secondary infertility is more likely to be caused 
by ‘preventable/acquired factors’, such as recurrent exposure 
to STIs, as opposed to primary infertility, which is more likely 
to be caused by non- preventable genetic/congenital abnormali-
ties.3 66 67
These findings attest to the potential role of gonorrhoea, 
and/or possibly other STIs associated with gonorrhoea, such 
as chlamydia, in infertility. Since early detection and treatment 
of gonococcal infections have been challenged by infection’s 
asymptomatic nature,68 69 and growing antimicrobial resist-
ance,22–26 these findings support the global public health value 
of developing gonococcal vaccines29 30 as a fundamental solu-
tion to gonorrhoea’s adverse implications.70 These findings also 
support the timeliness of a comprehensive prevention approach 
promoting sexual health to control N. gonorrhoeae and other 
STIs, mitigate antimicrobial resistance and achieve WHO global 
health sector strategy targets.21 Such an approach would focus 
on the simultaneous implementation of biomedical (rolling- out 
testing and vaccination), behavioural (promoting healthier sexual 
lives) and structural prevention interventions (improving access 
to testing, treatment and care services). Indeed, successful and 
sustainable implementation of biomedical interventions cannot 
be achieved without adequate levels of public awareness, access 
to/uptake of services, and adherence/retention in prevention and 
treatment cascades.
Interestingly, there was evidence of declining prevalence by 
~3% per year over the last four decades, possibly mirroring 
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Table 2 Results of univariable metregression analyses for the prevalence of NG infection in infertile populations
Predictors
studies/strata samples univariable analyses
Variance 
explained
Total n Total n Or (95% CI) P value* r2 (%)
Population 
characteristics
WHO region AMRO 33 7960 1.00 5.1
AFRO 24 2281 3.95 (1.54 to 10.09) 0.004
EMRO 14 1550 1.37 (0.45 to 4.19) 0.576
EURO 73 8987 1.32 (0.64 to 2.76) 0.452
SEARO 15 1207 1.24 (0.42 to 3.70) 0.692
WPRO 19 4905 1.23 (0.45 to 3.37) 0.686
Multicenter 6 374 8.96 (1.90 to 42.29) 0.006
Sex Men 43 16 560 1.00 2.0
Women 141 10 704 1.98 (1.06 to 3.67) 0.031
Infertility type Primary/majority primary 52 9330 1.00 0.7
Secondary/majority secondary 24 1756 2.14 (0.88 to 5.17) 0.091
Not specified/not applicable 108 16 178 1.06 (0.58 to 1.95) 0.840
Infertility diagnosis General infertility/not specified 64 12 441 1.00 4.7
Tubal factor infertility 50 3238 2.39 (1.23 to 4.63) 0.010
Male factor infertility 24 8263 0.72 (0.31 to 1.67) 0.442
Ovarian and non- tubal infertility 26 2255 0.80 (0.36 to 1.81) 0.595
Mixed and unexplained infertility 20 1067 2.03 (0.83 to 4.98) 0.122
Presence of urogenital 
signs and symptoms
Asymptomatic 64 16 484 1.00 8.2
Symptomatic 24 1408 5.94 (2.61 to 13.54) <0.001
Not specified 96 9372 1.67 (0.96 to 2.91) 0.070
Study methodology 
characteristics
Assay type NAAT (current infection) 33 12 594 1.00 22.0
Culture (current infection) 94 9682 2.54 (1.34 to 4.83) 0.005
Other† (current infection) 7 458 4.08 (1.09 to 15.27) 0.037
IgG (ever infection) 25 1470 22.10 (9.53 to 51.20) <0.001
IgA/unclear 25 3060 3.74 (1.61 to 8.67) 0.002
Year of data collection‡ 184 27 264 0.97 (0.95 to 0.99) 0.001 5.5
Sample size <100 participants 81 3803 1.00 3.0
≥100 participants 103 23 461 0.51 (0.30 to 0.86) 0.011
Risk of bias domains Infertility definition Follows WHO definition 70 11 293 1.00 0
Otherwise/unclear 114 15 971 0.85 (0.49 to 1.46) 0.549
Exposure to antimicrobials Lack of exposure last week 25 2037 1.00 2.2
Exposure in last week 9 1503 0.91 (0.23 to 3.61) 0.890
Unclear 150 23 724 2.27 (1.06 to 4.90) 0.036
Infection ascertainment Consistency in assay used 179 26 612 1.00 0
Otherwise/Unclear 5 652 1.30 (0.25 to 6.66) 0.750
Response rate ≥80% 2 70 1.00 0
<80%/unclear 182 27 194 0.78 (0.06 to 10.10) 0.849
*Strength of evidence for an association with prevalence was deemed ‘good’ at 0.05<p value≤0.10, and ‘strong’ at p value≤0.05.
†Includes Gram stain, gonozyme and fluorescent antibody assays.
‡Missing values for year of data collection were imputed using data for year of publication adjusted by the median difference between year of publication and year of data 
collection (for studies with complete information).
AFRO, African Region; AMRO, Region of the Americas; EMRO, Eastern Mediterranean Region; EURO, European Region; NAAT, nucleic acid amplification test; NG, Neisseria 
gonorrhoeae; SEARO, South- East Asia Region; WPRO, Western Pacific Region.
declines in prevalence in the population at large,71 72 or growing 
STI testing and treatment coverage, and use of improved diagnos-
tics in infertility workup.73 There was also evidence of regional 
variability in prevalence, with AFRO being most affected. This 
may reflect variability in background prevalence: AFRO has the 
highest gonorrhoea prevalence in the general population.11
The higher infection levels in infertile women compared 
with men, possibly reflect larger contribution of gonorrhoea to 
infertility in women (online supplementary figure 14),74 higher 
susceptibility to gonorrhoea acquisition in women75 or persis-
tence for longer durations, as this infection is largely asympto-
matic in women.68 69 As signs and symptoms are indicative of 
infection sequelae,76 gonorrhoea prevalence was higher in symp-
tomatic compared with asymptomatic individuals.
There were differences in prevalence by assay type, a result 
difficult to interpret given differences in sensitivity and speci-
ficity,73 and recent and differential use of NAAT in resource- rich 
versus resource- limited settings.73 Of note, the variation in the 
use of assays across settings and time is not likely to differentially 
affect one population, such as infertile populations, as opposed 
to another, such as the general population. While ever infection 
prevalence was much higher than current infection prevalence, 
this finding has probably limited epidemiological relevance, 
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Key messages
 ► Current gonorrhoea infection prevalence in infertile 
populations varied across regions but was several folds 
higher than that for the general population across world 
regions.
 ► Twice higher odds of gonorrhoea infection were found in 
women with tubal factor infertility and secondary infertility.
 ► A fraction of observed infertility is possibly preventable by 
controlling Neisseria gonorrhoeae transmission.
given cross- reaction with other pathogens, such as Staphylo-
coccus aureus.73 77 78
Our study has unavoidable limitations. Data quantity and 
quality varied across regions and sometimes limited our ability 
to produce representative summary estimates; there were only 
six studies assessing current infection in SEARO, all from India. 
It was not possible to conduct full multivariable metaregression 
to adjust for potential confounders, with the large number of 
predictors relative to that of studies. Prevalence estimates by 
infertility diagnosis may have been affected by unavoidable 
overlap across categories; samples with mixed infertility often 
included TFI, and those with non- TFI may have included other 
infertility diagnoses. An analysis by age could not be performed, 
given the low number of studies reporting patients’ age. There 
was evidence for small- study effect in metaregression (table 2 
and online supplementary table 12), suggesting publication 
bias; studies with small sample size reported higher prevalence. 
Conversely, differential access to quality STI testing and treat-
ment in infertility clinics, in settings with better versus limited 
access to STI services, may have biassed such studies towards 
lower prevalence.10 79–81 Risk of bias assessment was limited 
by studies with missing information. Gonorrhoea prevalence 
was often reported as a secondary outcome, with no ‘gonor-
rhoea’ term listed in title/abstract, thereby complicating study 
identification.
In conclusion, gonorrhoea prevalence in infertile populations 
is several folds higher than that in the general population. This 
finding, along with even higher prevalence in women with TFI 
and individuals with secondary infertility, attests to the potential 
role of N. gonorrhoeae in infertility and suggests that a fraction 
of infertility is possibly preventable by controlling N. gonor-
rhoeae transmission. Expansion of N. gonorrhoeae surveillance 
and monitoring in infertile populations is warranted as gaps in 
evidence persist. A multifaceted response should be considered 
to ensure progress towards WHO global health sector strategy 
targets.21
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